CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US6090914A · kind A · utility
79Cited by
3References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 1994 |
| Grant date | Jul 18, 2000 |
| Priority date | — |
| Expiry date | Apr 15, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins including CTLA4/CD28 chimeric proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.